Cargando…

Adding pharmacogenomics to the development of new marine-derived anticancer agents

Nature has always been a highly productive tool in the development of anticancer therapies. Renewed interest in the potential of this tool has recently been sparked by the realization that the marine ecosystem can be used for the discovery and development of new compounds with clinical potential in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimeno, José, Aracil, Miguel, Tercero, Juan Carlos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1334219/
https://www.ncbi.nlm.nih.gov/pubmed/16401350
http://dx.doi.org/10.1186/1479-5876-4-3
_version_ 1782126567874363392
author Jimeno, José
Aracil, Miguel
Tercero, Juan Carlos
author_facet Jimeno, José
Aracil, Miguel
Tercero, Juan Carlos
author_sort Jimeno, José
collection PubMed
description Nature has always been a highly productive tool in the development of anticancer therapies. Renewed interest in the potential of this tool has recently been sparked by the realization that the marine ecosystem can be used for the discovery and development of new compounds with clinical potential in advanced resistant tumors. These compounds can be incorporated into combination approaches in a chronic therapy scenario. Our marine anticancer program is using the sea to develop new agents with activity in resistant solid tumors and to identify new cellular targets for therapeutic intervention. This review describes the integration of different pharmacogenomic tools in the development of Yondelis™, Aplidin(® )and Kahalalide F, three marine-derived compounds currently in Phase II or III development. Our results are reinforcing the targeted selectivity of these agents and opening the gates for customized therapies in cancer patients in the near future.
format Text
id pubmed-1334219
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13342192006-01-19 Adding pharmacogenomics to the development of new marine-derived anticancer agents Jimeno, José Aracil, Miguel Tercero, Juan Carlos J Transl Med Review Nature has always been a highly productive tool in the development of anticancer therapies. Renewed interest in the potential of this tool has recently been sparked by the realization that the marine ecosystem can be used for the discovery and development of new compounds with clinical potential in advanced resistant tumors. These compounds can be incorporated into combination approaches in a chronic therapy scenario. Our marine anticancer program is using the sea to develop new agents with activity in resistant solid tumors and to identify new cellular targets for therapeutic intervention. This review describes the integration of different pharmacogenomic tools in the development of Yondelis™, Aplidin(® )and Kahalalide F, three marine-derived compounds currently in Phase II or III development. Our results are reinforcing the targeted selectivity of these agents and opening the gates for customized therapies in cancer patients in the near future. BioMed Central 2006-01-09 /pmc/articles/PMC1334219/ /pubmed/16401350 http://dx.doi.org/10.1186/1479-5876-4-3 Text en Copyright © 2006 Jimeno et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Jimeno, José
Aracil, Miguel
Tercero, Juan Carlos
Adding pharmacogenomics to the development of new marine-derived anticancer agents
title Adding pharmacogenomics to the development of new marine-derived anticancer agents
title_full Adding pharmacogenomics to the development of new marine-derived anticancer agents
title_fullStr Adding pharmacogenomics to the development of new marine-derived anticancer agents
title_full_unstemmed Adding pharmacogenomics to the development of new marine-derived anticancer agents
title_short Adding pharmacogenomics to the development of new marine-derived anticancer agents
title_sort adding pharmacogenomics to the development of new marine-derived anticancer agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1334219/
https://www.ncbi.nlm.nih.gov/pubmed/16401350
http://dx.doi.org/10.1186/1479-5876-4-3
work_keys_str_mv AT jimenojose addingpharmacogenomicstothedevelopmentofnewmarinederivedanticanceragents
AT aracilmiguel addingpharmacogenomicstothedevelopmentofnewmarinederivedanticanceragents
AT tercerojuancarlos addingpharmacogenomicstothedevelopmentofnewmarinederivedanticanceragents